SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

24 Jan 2026 Evaluate
The Sales for the quarter ended December 2025 of Rs. 0.00 million declined by -100.00% from Rs. 0.06 millions.The Total revenue for the quarter ended December 2025 of  Rs. 676.25  millions  grew by 29430.57% from Rs. 2.29 millions.Operating profit Margin for the quarter ended December 2025 slipped to -12.64% as compared to 4.22% of corresponding quarter ended December 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 0.00 0.06 -100.00 2863.82 3650.38 -21.55 16730.75 16856.32 -0.74
Other Income 6.61 4.65 42.15 10.37 17.05 -39.18 18.91 130.30 -85.49
PBIDT -12.64 4.22 -399.53 -631.11 408.77 -254.39 -245.67 1661.35 -114.79
Interest 302.25 0.00 0.00 489.20 199.78 144.87 745.78 871.42 -14.42
PBDT 566.62 4.22 13327.01 -238.80 208.99 -214.26 -991.45 789.93 -225.51
Depreciation 0.62 0.70 -11.43 167.82 159.80 5.02 623.89 607.18 2.75
PBT 566.00 3.52 15979.55 -406.62 49.19 -926.63 -1615.34 182.75 -983.91
TAX -110.25 1.23 -9063.41 -447.26 19.49 -2394.82 -478.53 132.74 -460.50
Deferred Tax -110.25 1.23 -9063.41 -447.26 19.49 -2394.82 -478.53 132.74 -460.50
PAT 676.25 2.29 29430.57 40.64 29.70 36.84 -1136.81 50.01 -2373.17
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 0.00 7033.33 0.00 -22.04 11.20 -296.80 -1.29 8.62 -114.91

Nectar Lifesciences Share Price

11.94 0.12 (1.02%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×